Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases. The current pipeline comprises programs in neurodegeneration including Alzheimer's and Parkinson's diseases, Tauopathies and Amyotrophic Lateral Sclerosis or Lou Gehrig's Disease. Based on its unique RTM™ technology platform (Reverse Translational Medicine), Neurimmune pursues a novel and revolutionary approach for the development of proprietary human monoclonal antibodies as therapeutics with unique advantages that result in superior risk profiles and excellent efficacy.
Neurimmune’s business strategy focuses on the discovery and development of human-derived antibodies through RTM™ at an early stage of the pharmaceutical value chain and partnering product candidates targeting significant markets and unmet medical needs with leading biopharmaceutical companies for later-stage development and marketing.
After its foundation in 2006, Neurimmune entered into a research and collaboration agreement with Biogen Idec Inc., a leading biopharmaceutical company to develop and commercialize novel treatments for Alzheimer’s disease in 2007, with an aggregate deal volume of $386 million plus double-digit royalties on net sales. Subsequently, Neurimmune applied its RTM™ technology platform to identify further therapeutic antibody candidates against important central nervous system (CNS) targets. In 2010, Neurimmune entered into a second deal with Biogen Idec with an additional aggregate volume of $427.5 million for the worldwide rights to three immunotherapy programs addressing alpha-synuclein, tau and TDP-43. These are believed to be central targets for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis (Lou Gehrig’s disease). Besides the CNS programs, Neurimmune expands its therapeutic indication areas with the goal to partner further programs with the biopharmaceutical industry to utilize complimentary resources and capabilities for drug development and to increase Neurimmune’s sustainable revenue stream.
Neurimmune's lead program on human monoclonal antibodies targeting beta-amyloid reached clinical trials status in patients with Alzheimer's disease in 2011.